AQS — Aequus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Aequus Announces Financing To Support Launch Of Zimed Preservative Free (Bimatoprost 0.03%) And Board Update
Brief: Aequus Announces Health Canada Notice Of Compliance For Zimed® Preservative Free
Brief: Aequus Announces Sandoz Contract Expiry At Year End And Expected Health Canada Approval For Zimed® Pf (Preservative Free)
Brief: Aequus Resumes Trading On TSX Venture Exchange
Brief: Aequus Provides Update On Delay In Filing Annual Financial Statements
Brief: Aequus Provides Update On Delay In Filing Annual Financial Statements
Brief: Sandoz And Aequus Agree To 1-Year Extension On Vistitan In Canada
Brief: Aequus Pharmaceuticals Inc - Commercial Relationship With Sandoz Regarding Glaucoma Medication Vistitan Will Remain In Place Until Feb 2022
Brief: Aequus Pharmaceuticals Inc Launches Evolve Eyedrops To Eye Care Professionals In Canada
Brief: Aequus Pharma Says Newly Approved Evolve Eye Drops Will Launch Early 2021 In Canada
Brief: Aequus Pharma Inc Reports Q3 Net Loss Of $251,921
Brief: Aequus Receives Approval For New Lubricating Eye Drops In Canada
Brief: Aequus Extends Commercial Agreement For Specialty Product Tacrolimus IR In Canada
Brief: Aequus Announces Expansion of Medicom Partnership and Filing with Health Canada
Brief: Aequus Announces Filing Of New Medical Device License For Evolve Dry Eye Products In Canada
Brief: Aequus Prepares For Health Canada Regulatory Filing As Partner Receives Mdsap Certificate For Dry Eye Products
Brief: Aequus Pharmaceuticals - Suspended In-Field Clinic And Hospital Visits For Time Being
Brief: Aequus Receives Positive Formulary Decision In British Columbia For Specialty Product
Brief: Aequus To Broaden Vistitan Reimbursement For Patients In Canada